Viral vector production

Using a PKC activator with an HDAC inhibitor enhances viral vector titer and cell viability, overcoming production challenges in GMP-grade vector manufacturing.

JP2026086450APending Publication Date: 2026-05-26OXFORD BIOMEDICA (UK) LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
OXFORD BIOMEDICA (UK) LTD
Filing Date
2026-01-16
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Existing methods for producing Good Manufacturing Practice (GMP) grade viral vectors face challenges in maximizing titer during production, influenced by factors such as viral serotype, transgene sequence, medium composition, transfection reagents, and cell viability, necessitating alternative production methods.

Method used

The use of a PKC activator, either alone or in combination with an HDAC inhibitor, during viral vector production to enhance titer and maintain cell viability, particularly for lentiviral vectors.

Benefits of technology

Significantly increases viral vector titer and maintains high cell viability, addressing bottlenecks in GMP-grade vector production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026086450000039
    Figure 2026086450000039
  • Figure 2026086450000040
    Figure 2026086450000040
  • Figure 2026086450000041
    Figure 2026086450000041
Patent Text Reader

Abstract

This provides a novel method for producing viral vectors. [Solution] A method for producing a viral vector, comprising culturing cells containing nucleic acid sequences encoding viral vector components in a cell culture medium containing a PKC activator.
Need to check novelty before this filing date? Find Prior Art